Want to see TELA full AI Analyst Report?
TELA Stock Chart & Stats
$0.74
$0.04(1.41%)
At close: 4:00 PM EST
$0.74
$0.04(1.41%)
Day’s Range― - ―
52-Week Range$0.50 - $2.19
Previous CloseN/A
Volume34.27K
Average Volume (3M)90.44K
Market Cap
$37.92M
Enterprise Value$55.31M
Total Cash (Recent Filing)$39.54M
Total Debt (Recent Filing)$56.39M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 12, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding44,766,148
10 Day Avg. Volume68,447
30 Day Avg. Volume90,440
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)8.78
Price to Sales (P/S)0.69
P/FCF Ratio-1.93
Enterprise Value/Market Cap1.46
Enterprise Value/Revenue0.68
Enterprise Value/Gross Profit1.02
Enterprise Value/Ebitda-1.70
Forecast
1Y Price Target
$1.67Price Target Upside125.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$86.71M
Bulls Say, Bears Say
Bulls Say
New Fully Resorbable Product (OviTex LTR)A differentiated, fully resorbable hernia implant broadens the addressable market and provides a sustainable competitive advantage versus nonresorbable alternatives. Durable clinical adoption and comparable pricing preserve revenue per procedure while enabling longer-term preference shifts among surgeons and hospitals.
High Gross Margins / Strong Product EconomicsSustained gross margins near the mid-to-high 60s imply durable unit-level profitability that can fund growth and absorb SG&A as the salesforce matures. With stable product economics, incremental revenue growth has a clearer path to improving operating leverage and eventual margin expansion.
Commercial Coverage Expansion & International TractionA fully staffed U.S. salesforce plus recent hiring cadence establishes durable coverage and capacity to penetrate accounts. As reps reach breakeven, productivity gains should be realized over multiple months, while international momentum provides a complementary, durable revenue growth channel.
Bears Say
Negative Equity And Meaningful DebtNegative equity and material debt weaken financial flexibility and increase refinancing risk. Over the coming months the company remains dependent on external capital if operating losses persist, raising structural funding pressure and potential dilution risk for shareholders.
Sustained Cash Burn And Negative Free Cash FlowOngoing negative operating and free cash flow, even if improved year-over-year, create a durable financing requirement over the next several quarters. This constrains the firm's ability to invest or withstand execution setbacks without raising capital, making growth contingent on funding or faster revenue conversion.
Execution And Timing Risk To Revenue RampRevenue and path to profitability rely on successful rep maturation, contract timing, and territory realignments. These operational dependencies persist for months; any lag in rep productivity or contract rollouts can materially delay cash-flow improvements and prolong losses.
TELA Bio News
TELA FAQ
What was TELA Bio’s price range in the past 12 months?
TELA Bio lowest stock price was $0.50 and its highest was $2.19 in the past 12 months.
What is TELA Bio’s market cap?
TELA Bio’s market cap is $37.92M.
When is TELA Bio’s upcoming earnings report date?
TELA Bio’s upcoming earnings report date is Aug 12, 2026 which is in 29 days.
How were TELA Bio’s earnings last quarter?
TELA Bio released its earnings results on May 12, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.184 by -$0.026.
Is TELA Bio overvalued?
According to Wall Street analysts TELA Bio’s price is currently Undervalued.
Does TELA Bio pay dividends?
TELA Bio does not currently pay dividends.
What is TELA Bio’s EPS estimate?
TELA Bio’s EPS estimate is -0.17.
How many shares outstanding does TELA Bio have?
TELA Bio has 44,766,148 shares outstanding.
What happened to TELA Bio’s price movement after its last earnings report?
TELA Bio reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.184. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of TELA Bio?
Currently, no hedge funds are holding shares in TELA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TELA Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.67 (125.23% Upside)
$1.67 (125.23% Upside)
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.55%
12-Months-Change
Fundamentals
Return on Equity
-1344.47%
Trailing 12-Months
Asset Growth
-9.53%
Trailing 12-Months
Company Description
TELA Bio
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
TELA Stock 12 Month Forecast
Average Price Target
$1.67
▲(125.23% Upside)
Technical Analysis
Cytosorbents
―
Sensus Healthcare
―
NeuroOne Medical Technologies
―
Pulmonx
―
Icecure Medical
―
Ownership Overview
20.74% Insiders
4.91% Mutual Funds
50.68% Other Institutional Investors
20.22% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---